Fosun Pharma, AriBio Sign Exclusive Global Option Agreement

Shanghai Fosun Pharmaceutical Co., Ltd. and AriBio Co., Ltd., a biopharmaceutical company focused on neurodegenerative diseases, have signed an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer’s disease (AD).

AR1001 is a best-in-class, once-daily oral phosphodiesterase-5 inhibitor with disease-modifying potential being developed for the treatment of Alzheimer’s disease. It is currently being evaluated in POLARIS-AD (NCT05531526), a global Phase 3 clinical trial for early AD. Enrollment was completed in 2025, and top-line results are anticipated in 2026. AR1001 has demonstrated therapeutic effects through multiple mechanisms, including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow. Preclinical and clinical data to date indicate a favorable safety profile, blood-brain barrier penetration, and potential therapeutic benefit in patients with early AD, ranging from mild cognitive impairment to mild dementia.

Terms of the Agreement

This agreement further deepens and expands the successful prior collaboration, under which Fosun Pharma secured rights to develop, register, manufacture and commercialize AR1001 in Chinese mainland, Hong Kong and Macao as well as in ten designated ASEAN countries.

With today’s agreement, the partnership is extended to global markets, including major regions such as the United States, Europe and Japan. Going forward, both parties will leverage Fosun Pharma’s established capabilities in R&D, manufacturing, regulatory affairs and commercialization to accelerate the global launch of AR1001.

The transaction adopts an “option fee plus license payment” structure. Fosun Pharma will pay AriBio a $60 million option fee and retains the right to decide whether to exercise the option within the agreed exercise period. Upon exercise of the option, Fosun Pharma will pay up to $180 million in upfront and regulatory milestone payments. Sales milestone payments will be triggered when annual net sales of the licensed product reach at least $2.5 billion.

“This global partnership with Fosun Pharma represents a transformational milestone in our mission to bring innovative treatments to Alzheimer’s disease patients and families worldwide, one of the most pressing unmet medical needs of our time” said Jai Jun Choung, PhD, Chairman and Co-CEO of AriBio. “Fosun Pharma’s proven global capabilities and shared commitment to tackling AD make them an ideal partner to advance AR1001. We look forward to working closely together to accelerate toward commercial launch and furthering our broader strategic collaboration.”

Guo Guangchang, Chairman of Fosun International, said, “Our global partnership with AriBio marks a significant step in Fosun’s international strategy in innovative medicines, and reflects our long-term commitment to addressing major diseases by integrating global resources to improve the health and well-being of families around the world.”